{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:43:33Z","timestamp":1775666613521,"version":"3.50.1"},"reference-count":36,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2013,1,31]]},"DOI":"10.2217\/fon.12.168","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T16:31:57Z","timestamp":1355934717000},"page":"21-29","source":"Crossref","is-referenced-by-count":5,"title":["Pralatrexate: Treatment of T-Cell Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1080","volume":"9","author":[{"given":"Terri","family":"Parker","sequence":"first","affiliation":[{"name":"Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT06520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Barbarotta","sequence":"additional","affiliation":[{"name":"Yale-New Haven Hospital, 20 York Street, New Haven, CT06520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT06520, USA"},{"name":"Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT06520, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.010"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3452.3452"},{"key":"e_1_3_2_3_5_1","unstructured":"NCCN Guidelines\u2122 Non-Hodgkin\u2019s Lymphomas Panel\n. NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphomas. National Comprehensive Cancer Network Fort Washington PA USA(9 July 2012)."},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600961058"},{"issue":"15","key":"e_1_3_2_3_11_1","article-title":"Activity of lenalidomide in a Phase II trial for T-cell lymphoma: report on the first 24 cases.","volume":"27","author":"Dueck GS","year":"2009","unstructured":"Dueck GS , ChuaN, PrasadAet al. Activity of lenalidomide in a Phase II trial for T-cell lymphoma: report on the first 24 cases. J. Clin. Oncol. 27(15S), Abstract 8524 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11899"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.2146\/news090080"},{"key":"e_1_3_2_3_20_1","unstructured":"Sirotnak FM SchmidFA SamuelsLL DegrawJI. 10-ethyl-10-deaza-aminopterin: structural design and biochemical pharmacologic and antitumor properties.NCI Monogr. (5) 127\u2013131 (1987)."},{"key":"e_1_3_2_3_21_1","first-page":"43","volume-title":"Folate Antagonists as Therapeutic Agents","author":"Sirotnak FM","year":"1984","unstructured":"Sirotnak FM , DegrawJI. Selective antitumor action of folate analogs. In: Folate Antagonists as Therapeutic Agents. SirotnakFM, BurchallJJ, EnsmingerWD, MontgomeryJA (Eds). Academic Press, Inc., NY, USA, 43\u201395 (1984)."},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050823"},{"issue":"1","key":"e_1_3_2_3_23_1","first-page":"26","article-title":"New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.","volume":"12","author":"Sirotnak FM","year":"1984","unstructured":"Sirotnak FM , DegrawJI, SchmidFA, GoutasLJ, MoccioDM. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.Cancer Chemother. Pharmacol.12(1), 26\u201330 (1984).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"e_1_3_2_3_24_1","unstructured":"Izbicka E DiazA CamposD WickM SteffenR SaundersM. Differential activity and potential mechanism of action of pralatrexate (PDX) methotrexate and pemetrexed (Alimta) in human cancer models in vivo and in vitro. Proceedings of AACR\u2013NCI\u2013EORTC International Conference Molecular Targets and Cancer Therapeutics: Discovery Biology and Clinical Applications . San Francisco CA USA 22\u201326 October 2007."},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0954-4"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"crossref","unstructured":"Venitz J BrarSS PronkGJet al. Pralatrexate pharmacokinetics with intravenous administration to oncology patients (poster # B211). Presented at: AACR\u2013NCI\u2013EORTC Internation Conference: Molecular Targets and Therapeutics Boston MA USA 15\u201319 November 2009.","DOI":"10.1158\/1535-7163.TARG-09-B211"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1214"},{"key":"e_1_3_2_3_28_1","unstructured":"FOLOTYN \u00ae prescribing information\/package insert. Allos Therapeutics USA (2011)."},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077124"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0331"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0671"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.80"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1674.1674"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.01.010"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390211"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.12.168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:41:53Z","timestamp":1719124913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.12.168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,31]]}},"alternative-id":["10.2217\/fon.12.168"],"URL":"https:\/\/doi.org\/10.2217\/fon.12.168","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,19]]}}}